MX2018008272A - Compuestos antagonizantes del receptor a3 de la adenosina, metodo para prepararlos y uso medico de los mismos. - Google Patents

Compuestos antagonizantes del receptor a3 de la adenosina, metodo para prepararlos y uso medico de los mismos.

Info

Publication number
MX2018008272A
MX2018008272A MX2018008272A MX2018008272A MX2018008272A MX 2018008272 A MX2018008272 A MX 2018008272A MX 2018008272 A MX2018008272 A MX 2018008272A MX 2018008272 A MX2018008272 A MX 2018008272A MX 2018008272 A MX2018008272 A MX 2018008272A
Authority
MX
Mexico
Prior art keywords
adenosine receptor
medical
preparing
compounds
glaucoma
Prior art date
Application number
MX2018008272A
Other languages
English (en)
Inventor
Koo Hyeon Ahn
Jinhwa Lee
Kim Seungyong
Kim Doran
Bin Lee Gwi
Sook Hwang Hyun
Original Assignee
Handok Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Handok Inc filed Critical Handok Inc
Publication of MX2018008272A publication Critical patent/MX2018008272A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona compuestos útiles para el alivio, prevención o tratamiento de las enfermedades mediadas por el receptor A3 de la adenosina, tales como el glaucoma y los trastornos oculares relacionados con el glaucoma, que tienen la estructura de la Fórmula I, como se define en la descripción detallada; las composiciones farmacéuticas que comprenden al menos uno de los compuestos; y métodos para aliviar, prevenir o tratar las enfermedades mediadas por el receptor A3 de la adenosina utilizando el compuesto.
MX2018008272A 2016-01-14 2017-01-13 Compuestos antagonizantes del receptor a3 de la adenosina, metodo para prepararlos y uso medico de los mismos. MX2018008272A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662278897P 2016-01-14 2016-01-14
PCT/KR2017/000492 WO2017123058A1 (en) 2016-01-14 2017-01-13 Compounds antagonizing a3 adenosine receptor, method for preparing them, and medical-use thereof

Publications (1)

Publication Number Publication Date
MX2018008272A true MX2018008272A (es) 2019-01-31

Family

ID=59311929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008272A MX2018008272A (es) 2016-01-14 2017-01-13 Compuestos antagonizantes del receptor a3 de la adenosina, metodo para prepararlos y uso medico de los mismos.

Country Status (11)

Country Link
US (1) US10196396B2 (es)
EP (1) EP3402798B1 (es)
JP (1) JP2019501949A (es)
KR (1) KR20180095723A (es)
CN (1) CN108463463A (es)
BR (1) BR112018014525A2 (es)
CA (1) CA3011442A1 (es)
HK (1) HK1254892A1 (es)
MX (1) MX2018008272A (es)
RU (1) RU2737157C2 (es)
WO (1) WO2017123058A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201841916A (zh) * 2017-04-12 2018-12-01 美商麥珍塔治療學股份有限公司 芳香烴受體拮抗劑及其用途
US20220281873A1 (en) * 2019-07-08 2022-09-08 Medshine Discovery Inc. Compound as porcupine inhibitor and use thereof
KR102623069B1 (ko) 2021-03-08 2024-01-10 주식회사 한독 섬유증의 치료 또는 완화용 약학 조성물
WO2023072263A1 (zh) * 2021-10-29 2023-05-04 南京明德新药研发有限公司 5-取代的吡啶-2(1h)-酮类化合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
EP2311806A3 (en) 1996-01-29 2011-08-10 The United States of America, Represented by the Secretary, Department of Health and Human Services Dihydropyridine-, pyridine-, benzopyranone- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists
UA51716C2 (uk) * 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
CA2337499A1 (en) 1998-07-16 2000-01-27 The Trustees Of The University Of Pennsylvania Methods for reducing intraocular pressure using a3-adenosine antagonists
WO2002096318A2 (en) * 2001-05-30 2002-12-05 Alteon, Inc. Method for treating glaucoma v
ES2293068T3 (es) 2002-09-19 2008-03-16 Schering Corporation Imidazopiridinas como inhibidores de quinasas dependientes de ciclina.
AU2003301589A1 (en) 2002-10-25 2004-05-13 Ewha Womans University Purine nucleosides
AU2007307157A1 (en) * 2006-10-06 2008-04-17 The Trustees Of The University Of Pennsylvania Effective delivery of cross-species A3 adenosine-receptor antagonists to reduce intraocular pressure
CN101646434A (zh) 2006-11-09 2010-02-10 公共健康研究中心 腺苷拮抗剂的用途
CN101801970B (zh) 2007-03-07 2013-11-06 Fm治疗股份有限公司 腺苷衍生物、用于合成其的方法和包含其作为活性成分的用于预防和治疗炎症疾病的药物组合物
US8329697B2 (en) * 2008-02-26 2012-12-11 Merck Sharp & Dohme Corp. Imidizo[1,2-A]pyrazines useful as AHCY hydrolase inhibitors
EP2388253B1 (en) 2009-03-10 2015-02-11 Gifu University Thiazole derivative and process for producing same
DK2899191T3 (da) * 2009-04-30 2017-11-13 Glaxo Group Ltd Oxazol-substituerede indazoler som pi3-kinaseinhibitorer
AR079234A1 (es) 2009-12-01 2012-01-04 Abbott Lab Derivados heterociclicos condensados nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar afecciones oncologicas, del sistema nervioso y/o del sistema inmune.
MX2012010006A (es) * 2010-03-03 2013-01-17 Us Gov Health & Human Serv Agonistas de a3ar para el tratamiento de uveitis.
TW201210584A (en) * 2010-08-18 2012-03-16 Alcon Res Ltd Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma

Also Published As

Publication number Publication date
HK1254892A1 (zh) 2019-08-02
BR112018014525A2 (pt) 2018-12-11
JP2019501949A (ja) 2019-01-24
RU2737157C2 (ru) 2020-11-25
KR20180095723A (ko) 2018-08-27
EP3402798A1 (en) 2018-11-21
EP3402798B1 (en) 2021-04-28
CN108463463A (zh) 2018-08-28
RU2018129433A (ru) 2020-02-14
US20170204101A1 (en) 2017-07-20
RU2018129433A3 (es) 2020-02-26
US10196396B2 (en) 2019-02-05
WO2017123058A1 (en) 2017-07-20
CA3011442A1 (en) 2017-07-20
EP3402798A4 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2021009673A (es) Moduladores de ror-gamma.
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2015101957A3 (en) Inhibitors of glutaminase
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
TN2016000458A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer.
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
MX2018004954A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer.
GB2533454A (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
WO2016109217A3 (en) Btk inhibitors
MX2018008272A (es) Compuestos antagonizantes del receptor a3 de la adenosina, metodo para prepararlos y uso medico de los mismos.
WO2017177004A8 (en) Tertiary amides and method of use
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
PH12021550872A1 (en) Therapeutic compounds
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
WO2018118791A3 (en) Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
MY201535A (en) Therapeutic compounds
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
WO2017168454A3 (en) Novel compounds as btk inhibitors